Minor
REVEAL-ND NPM1 · Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Trial sites expanded: 109 → 149 locations
Syndax PharmaceuticalsPhase 3 NCT07211958 Registry history of NCT07211958 on ClinicalTrials.gov (opens the registry)